Strategic partnerships Leverage VERAXA’s collaboration with OmniAb and their bsADC focus to position joint development or co-commercialization opportunities, offering complementary discovery, conjugation, and optimization capabilities that accelerate lead candidates.

Clinical pipeline momentum Highlight recent milestones such as advancing VXA-222 and the BiTAC platform progress to prospective collaborators or funding partners, framing opportunities around rapid translation of novel antibodies into clinical development.

Biotech growth readiness Target mid-stage biotech and specialty pharma seeking to augment in-house capabilities with VERAXA’s proprietary linker technologies and conjugation expertise to de-risk and speed ADC/bsADC programs.

Strategic hiring signals Monitor leadership changes, notably the appointment of a new chief scientific officer, as indicators of strategic pivots or expanded research focus, presenting opportunities for advisory, collaboration, or technology licensing discussions.

Cancer therapeutics emphasis Align outreach with the company’s stated focus on novel antibody therapies against cancer, offering targeted IDE/experimentation services, preclinical collaboration, and access to specialized assay development and tox-/efficacy testing.